Mostrar Noticias:

GILDPrincipalesÚltima Hora

 Ver noticias de otros activos

Búsqueda de noticias relacionadas a la acción Gilead Sciences (ordenadas por fecha):

«Hay que optimizar el uso de medicamentos para que no haya abusos» El Norte de Castilla La gestión de la crisis centrará las V Jornadas de Gestión Aplicada a la Farmacia Hospitalaria, que se celebran desde hoy y hasta este viernes en La Granja de San Ildefonso, patrocinadas por Gilead Sciences. Los recortes en la dotación económica ... A corto-medio plazo harán falta más farmacéuticos de hospital en España para ...Asturi.as los 13 artículos informativos »

Gilead Sciences anuncia resultados financieros correspondientes al primer ... Finanzas.com Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado hoy los resultados de sus operaciones para el trimestre cerrado el 31 de marzo, 2012. Los ingresos brutos totales para el primer trimestre de 2012 se elevaron a $2.280 millones, un aumento del 19% en ... y más »

El Comité Asesor de la FDA respalda la aprobación del régimen Quad de única ... elEconomista.es Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado que el Comité Asesor de Fármacos Antivirales de la Agencia de Alimentos y Fármacos de Estados Unidos (FDA en sus siglas en inglés) ha votado 13 a 1 en apoyo a la aprobación del Quad, un régimen completo ... y más »

Los hospitales acaparan el 40% del gasto nacional en medicamentos El Norte de Castilla Así lo ha hecho saber el presidente de la Sociedad Española de Farmacia Hospitalaria (SEFH), José Luis Poveda, en la presentación de las quintas Jornadas de Gestión aplicada a la Farmacia Hospitalaria, patrocinadas por Gilead Sciences SL Este foro ...

El Universo

El Comité Asesor de la FDA respalda la aprobación de Truvada® de Gilead para ... elEconomista.es Gilead Sciences, Inc. (Nasdaq:GILD) ha anunciado que el Comité Asesor de Fármacos Antivirales de la Agencia de Alimentos y Fármacos (FDA en sus siglas en inglés) de Estados Unidos, ha votado apoyar la aprobación de Truvada ® (emtricitabina y fumarato ... Expertos de Estados Unidos recomiendan por primera vez la aprobación de un ...Cuatro El comité de antivirales de la FDA avala el uso de Truvada para prevenir el VIHEl Global Píldora contra el VIH pasa la primera pruebaLa Opinion El Periódico Mediterráneo -Telemundo L.A. los 294 artículos informativos »

ElEspectador.com

Estados Unidos da luz verde al primer fármaco preventivo del sida ABC.es De aprobarse este medicamento, registrado como «Truvada» por Gilead Sciences, se trataría del primer medicamento para el control de la infección por VIH, el virus del sida . El fármaco de Gilead combina tenofovir ?conocido como «Viread»- y ... Un comité de expertos de la FDA respalda el primer fármaco preventivo del VIHEl País.com (España) Recomiendan autorizar primer fármaco para prevenir el sidaEl Universal - Cartagena Encuentran científicos fármaco que puede prevenir el sidaeNewspaper Perfil.com -Vanguardia.com.mx los 25 artículos informativos »

La Granja acogerá unas jornadas sobre la situación de la Farmacia Hospitalaria El Adelantado de Segovia Será del 23 al 25 de mayo en el marco de las V Jornadas de Gestión aplicada a la Farmacia Hospitalaria, patrocinadas por Gilead Sciences, SL que se celebrarán en La Granja de San Ildefonso. Los farmacéuticos de hospital tendrán, entre otras cosas, ...

Opinión Bolivia

??El sida, asesino implacable Opinión Bolivia La Truvada, fabricada por la farmacéutica Gilead Sciences, ayudó a prevenir el VIH en hombres sanos homosexuales que tenían comportamiento de riesgo en entre un 44 por ciento y un 73 por ciento . El fármaco está actualmente disponible como un ... y más »

AlianzaTex

Aprueban primer medicamento para prevenir el sida AlianzaTex Este es el medicamento 'Truvada' producido por el laboratorio Gilead Sciences AP / GILEAD SCIENCES ! LA VANGUARDIA | TEXCOCO PRESS Texcoco, México.- (Texcoco Mass Media).- Un panel de expertos de la Administración de Fármacos y Alimentos (FDA, ... Fármaco que previene contagio de VIH, cada vez más cercaTerra Perú los 80 artículos informativos »

Generación posguerra EEUU debería hacerse test hepatitis C: CDC Publico.es Compañías como Gilead Sciences y Bristol-Myers Squibb apuntan a mejorar esas medicinas con píldoras que no requieran ser combinadas con inyecciones para reforzar el sistema inmune, las cuales tienen efectos colaterales que pueden perjudicar a los ... y más »

GILEAD SCIENCES, INC. : Gilead Files European Marketing Application for ... 4-traders Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA). Cobicistat is Gilead's pharmacoenhancing or ... y más »

Gilead Sciences Inc: Large-cap Growth at an Attractive Price Green Faucet Global Market Commentaries ?Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases ... y más »

Gilead Sciences Inc.: Strong Growth At A LowPrice - Breaking News The Mumbai Times Gilead Sciences Inc (NASDAQ:GILD) shares were trading at $50.89 while reporting up 1.90% from yesterdays close. The 21 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 60.00, with a high estimate of 67.00 and a ... Gilead Sciences Inc.: Strong Growth At A Low PriceSeeking Alpha los 6 artículos informativos »

Daily Beast

Gilead Sciences' HIV Drugs Clear a Hurdle Investorplace.com The outlook for Gilead Sciences (NASDAQ:GILD) brightened substantially last week. A US government advisory panel recommended approval of Quad, the company's experimental four-in-one HIV drug, and the off-label use of Truvada, an existing drug, ... J.P. Morgan Reiterates Overweight Rating, $65 PT for Gilead SciencesBenzinga HIV/AIDS Experts: Prevention Pill Could Encourage Risky BehaviorBlack Voice News Newspapers examine concerns surrounding possible FDA approval of Truvada for PrEPNews-Medical.net SouthFloridaGayNews.com -Broward-Palm Beach New Times (blog) -Chicago Tribune los 467 artículos informativos »

New York Daily News

Gilead Sciences Inc (NASDAQ:GILD) shares were trading at $52.46 while ... The Mumbai Times Kidney issues don't look like they'll keep Gilead Sciences' (NAS: GILD) Quad HIV drug off the market -- an advisory panel recommended approving the drug by a 13-1 margin -- but they might result in extra monitoring for kidney complications once the ... Gilead Sciences HIV Drug Quad Gets FDA Panel BackingRTT News HIV Drug Maker Gilead Sciences Scores Two WinsMinyanville.com Gilead Sciences clears hurdle for pill to prevent HIVMSN Money BusinessWeek -Zacks.com los 226 artículos informativos »

CBS News

GILEAD SCIENCES, INC. : FDA Advisory Committee Supports Approval of Gilead 's ... 4-traders 11, 2012-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the US Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of ... Biz Break: Gilead pins hopes on HIV drug; Apple rumors; and chipmakers ...San Jose Mercury News Gilead's Pill Wins US Panel Backing to Prevent HIVBusinessWeek FDA Advisory Committee Supports Approval of Gilead's Truvada(R) for Reducing ...MarketWatch (press release) Chicago Tribune -Bloomberg -Atlanta Journal Constitution los 2.068 artículos informativos »

Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health ... MarketWatch (press release) FOSTER CITY, Calif., May 08, 2012 (BUSINESS WIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. y más »

Gilead deposita la domanda di autorizzazione alla commercializzazione dell ... ANSA.it Gilead Sciences, Inc. (Nasdaq: GILD) ha annunciato in data odierna che la domanda di autorizzazione alla commercializzazione (Marketing Authorisation Application, MAA) di cobicistat, depositata il 26 aprile us, è stata convalidata dall'agenzia europea ... y más »

What''s News / Internacional / Un panel de expertos de la FDA,? EntornoInteligente UU., decidirá esta semana si recomienda o no por primera vez que ciertas personas saludables, pero en riesgo de contagio, tomen una medicina que los ayude a prevenir el VIH. Truvada, el tratamiento de Gilead Sciences, es uno de los más usados para el ... y más »

RTT News

Gilead Sciences 1Q profit down on Pharmasset costs BusinessWeek HIV drug maker Gilead Sciences Inc.'s profit dropped 32 percent in the first quarter on costs related to its purchase of hepatitis C drug developer Pharmasset Inc. Gilead said Thursday that its profit fell to $442 million, or 57 cents per share, ... Gilead Sciences Q1 Profit Down - Quick FactsNASDAQ Gilead Sciences Management Discusses Q1 2012 Results - Earnings Call TranscriptSeeking Alpha Higher Costs Hurt GileadDaily Markets StreetInsider.com (subscription) los 42 artículos informativos »

Midday Glance: Biotechnology companies CBS News NEW YORK ? Shares of some top biotechnology companies are down at 1 pm: Amgen Inc. fell $.84 or 1.2 percent, to $68.07. Biogen Idec fell $.57 or .4 percent, to $131.76. Celgene Corp. fell $.91 or 1.3 percent, to $68.74. Gilead Sciences Inc. fell $.61 ... y más »

TheStreet.com

Vertex Is the Next Gilead Sciences or Alexion TheStreet.com (TheStreet) -- Vertex Pharmaceuticals(VRTX) is the next Gilead Sciences(GILD). You think I'm reaching? Okay, then Vertex is the next Alexion Pharmaceuticals(ALXN). Either way, the big move higher in Vertex's stock price Monday, spurred by the release ... 5 Biotech Stocks With Massive Upside Potential In 2013Seeking Alpha los 87 artículos informativos »

Gilead Sciences (GILD) - Market Recap AVAFIN NEW YORK (AVAFIN) -- A record number of Gilead Sciences call contracts were traded during the busy trading session. There were 3.1 call contracts traded for each put contract yielding a 0.32 put/call ratio where 3060 put and 9474 call contracts ... Updated: Gilead Sciences (GILD) - Market RecapThe Mumbai Times los 3 artículos informativos »

Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care ... MarketWatch (press release) FOSTER CITY, Calif., May 01, 2012 (BUSINESS WIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that its corporate presentation will be webcast from the Deutsche Bank 37th Annual Health Care Conference in Boston. John F. Milligan, PhD, ... AnaptysBio Announces Antibody Discovery Partnership With Gilead SciencesPR Newswire (press release) Health-Care Stocks on SaleBarron's los 13 artículos informativos »

Research Reports for Chesapeake Energy, Bank of America, Ford, Ciena, Nuance ... MarketWatch (press release) ... Bank of America (NYSE:BAC) , Ford (NYSE:F) , Ciena (NASDAQ:CIEN) , Nuance Communications (NASDAQ:NUAN) , and Gilead Sciences (NASDAQ:GILD) . (Read full report by clicking the link below, you may need to copy and paste the full link to your browser ... y más »

Breaking News: The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs ... The Mumbai Times Stocks recently featured in the blog include Gilead Sciences (GILD - Analyst Report), Abbott Labs (ABT - Analyst Report), Alliance Data Systems Corporation (ADS - Snapshot Report), Blue Nile (NILE - Snapshot Report) and Bristol-Myers Squibb (BMY ...

Ontario Venture Capital Fund commits $70 million to three leading venture ... DigitalJournal.com (press release) Some of the investments in the firm's most recent fund include, Kai Pharmaceuticals (acquired by Amgen), Pharmasset (acquired by Gilead Sciences), Ception Therapeutics (acquired by Cephalon), Resonant Medical (acquired by Elekta), Morphotek (acquired ... y más »

InPharm

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE] Minyanville.com (See: Arena Shares Sink as Big Dates for Diet Pill Makers Near.) Another FDA panel will debate a new use for Gilead Sciences' (GILD) HIV treatment Truvada. Gilead wants to market the drug as a preventative treatment against the AIDS virus. Protalix Wins FDA Approval for Its First Drug; ISTA Reports Positive, Results ...BioMedReports (subscription) los 99 artículos informativos »

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data ... Sacramento Bee Gilead Sciences (Nasdaq:GILD) received some encouraging news recently when an advisory panel of the US Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. A final decision from the FDA regarding the ... y más »

JPMorgan Chase Gives Overweight Rating to Gilead Sciences (GILD) Junction Report Gilead Sciences (NASDAQ: GILD)'s stock had its ?overweight? rating reiterated by investment analysts at JPMorgan Chase (NYSE: JPM) in a note issued to investors on Wednesday. They currently have a $65.00 target price on the stock. y más »

Final Glance: Biotechnology companies CBS News NEW YORK ? Shares of some top biotechnology companies were mixed at the close of trading: Amgen Inc. fell $.41 or .6 percent, to $68.91. Biogen Idec rose $.07 or .1 percent, to $132.33. Celgene Corp. rose $.23 or .3 percent, to $69.65. Gilead Sciences ... Midday Glance: Biotechnology companiesCNBC.com los 6 artículos informativos »

AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences MarketWatch (press release) SAN DIEGO, May 1, 2012 /PRNewswire via COMTEX/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics. y más »

Early Glance: Biotechnology companies CBS News NEW YORK ? Shares of some top biotechnology companies are mixed at 10 am: Amgen Inc. fell $.01 or percent, to $68.90. Biogen Idec rose $.07 or .1 percent, to $132.40. Celgene Corp. fell $.45 or .6 percent, to $69.20. Gilead Sciences Inc. fell $.15 or ...

Gilead Sciences Looks For Hepatitis C Cure Seeking Alpha When I last wrote about Gilead Sciences (GILD), on July 26, 2011, I said "A convergence of factors is driving Gilead profits higher. This trend should accelerate in 2012 and continue through at least 2015." [See Gilead Sciences Readies Pipeline]. Citigroup Sets Gilead Sciences Price Target at $64.00 (GILD)Daily Political Zacks Reiterates Neutral on Gilead Sciences (GILD)Junction Report los 4 artículos informativos »

Our Take: Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners ... The Mumbai Times Gilead Sciences Inc (NASDAQ:GILD) shares were trading at $50.10 while reporting down 2.87% from yesterdays close. The 21 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 60.00, with a high estimate of 67.00 and ... y más »

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May Minyanville.com (See: Arena Shares Sink as Big Dates for Diet Pill Makers Near.) Another FDA panel will debate a new use for Gilead Sciences' (GILD) HIV treatment Truvada. Gilead wants to market the drug as a preventative treatment against the AIDS virus. y más »

The biggest R&D spenders in biotech FierceBiotech Gilead ($GILD) bought its way into the hot race on hep C. Celgene ($CELG) has been aggressive on its own front, buying Avila and investing in new technology. And Vertex ($VRTX) showed that when you stay aggressive, and smart, you should never be ... y más »

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment ... MarketWatch (press release) FOSTER CITY, Calif., May 01, 2012 (BUSINESS WIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101 (formerly CAL-101). y más »

In Spotlight: Healthy Returns in Health Care? The Mumbai Times Gilead Sciences Inc (NASDAQ:GILD) shares were trading at $51.58 while reporting down 0.56% from yesterdays close. The 21 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 60.00, with a high estimate of 67.00 and ... y más »

Gilead Sciences begins phase III trial of leukaemia drug Zenopa Gilead Sciences has commenced a phase III clinical trial of GS-1101, a promising new therapy for previously treated chronic lymphocytic leukaemia (CLL). The first patient has been dosed as part of Study 116, a trial that will assess the safety and ... Gilead initiates Phase III chronic lymphocytic leukemia trialPharmaceutical Business Review los 2 artículos informativos »